Jubilant Life Sciences Limited Risk Report
Explore Jubilant Life Sciences Limited across six non‑financial risk dimensions:ESG, Workforce, News & Media, Cybersecurity, Legal & Regulatory, Operational. Unlock the full report, original sources and timelines, and enable continuous monitoring.
Summary
⚖️ Legal & Regulatory
Jubilant Life Sciences has encountered several legal and regulatory challenges that could impact its business operations. The company's Roorkee plant faced regulatory scrutiny, which required attention to regulatory compliance. Additionally, financial settlements and strategic partnerships shaped its regulatory landscape over the years.
- Jubilant Life Sciences settled a loan with IFC through a USD 135 million payout 🗓 March 29, 2019.
- The USFDA recommended regulatory action against Jubilant Life's Roorkee plant 🗓 December 8, 2018.
- SEBI imposed a penalty of Rs 50 lakh on Jubilant Life Sciences for unspecified reasons 🗓 January 31, 2018.
- Jubilant Life Sciences had to address concerns following a USFDA warning on its Nanjangud facility, indicating ongoing compliance issues 🗓 March 22, 2019.
📜 Innovation & R&D
Jubilant Life Sciences has actively engaged in innovation and research to expand its portfolio and market presence. The company frequently collaborates with partners to enhance its product offerings and has achieved significant milestones in its R&D initiatives.
- Jubilant Life Sciences selected CDD Vault to handle research communication for five years 🗓 May 8, 2019, aiming to improve collaboration and data management.
- Jubilant launched a generic version of Remdesivir for COVID-19 treatment 🗓 August 4, 2020, addressing urgent healthcare needs during the pandemic.
- The company entered several licensing agreements with Gilead to produce Remdesivir 🗓 May 12, 2020, highlighting its strategic moves in pharmaceuticals.
- Jubilant announced plans to launch Jubi-R for COVID-19 treatment 🗓 August 4, 2020, broadening its COVID-19 related offerings.
Profile
News & Media
Real‑time aggregation of trusted sources tracking company‑related events with sentiment and topic tags for rapid risk triage.
Sign up to unlock Jubilant Life Sciences Limited’s complete news feed with sentiment and topic tags.
View Full ReportEntity List
Continuous third‑party screening across global sanctions, enforcement, and watchlist sources with unified entity resolution and real‑time alerts.
| Name | Issuer | Status |
|---|---|---|
| ACF List of War Enablers | Anti-Corruption Foundation | |
| African Development Bank Debarred Entities | African Development Bank Group | |
| Argentina Members of Parliament | Honorable Cámara de Diputados de la Nación Argentina | |
| Argentina RePET Sanctions | Ministerio de Justicia | |
| Armenia Public Officials and Associates | Hetq Online | |
| Asian Development Bank Sanctions | Asian Development Bank | |
| Australian Sanctions Consolidated List | Department of Foreign Affairs and Trade | |
| Democratic People's Republic Of Korea (North Korea) Sanctions Regime | Department of Foreign Affairs and Trade | |
| Former Federal Republic Of Yugoslavia Sanctions Regime | Department of Foreign Affairs and Trade | |
| Iran Sanctions Regime | Department of Foreign Affairs and Trade |
Sign up to unlock Jubilant Life Sciences Limited’s sanctions, enforcement, and watchlist risk profile.
View Full ReportESG
Verification of declared ESG commitments and certifications with evidence links, score signals, and status updates across E, S, and G.
| Name | Status |
|---|---|
| Sustainable Finance Disclosure Regulation | |
| Global Reporting Initiative Standards | |
| EU Taxonomy Regulation | |
| EU Corporate Sustainability Reporting Directive | |
| California Transparency in Supply Chains Act | |
| EU Non-Financial Reporting Directive | |
| ISO 14001 | |
| Sustainability Accounting Standards Board Standards | |
| Task Force on Climate-related Financial Disclosures | |
| UN Guiding Principles on Business and Human Rights |
Sign up to unlock Jubilant Life Sciences Limited’s ESG commitments, certifications, and controversy signals.
View Full ReportCybersecurity
Verification of adherence to recognized security standards, mapping control coverage and gaps affecting third‑party and supply‑chain risk.
| Certification | Status |
|---|---|
| General Data Protection Regulation | |
| Digital Operational Resilience Act | |
| Cybersecurity Maturity Model Certification | |
| NIST Cybersecurity Framework | |
| NIST 800-53 Revision 5 | |
| California Consumer Privacy Act | |
| ISO/IEC 27001 | |
| Health Insurance Portability and Accountability Act | |
| Payment Card Industry Data Security Standard | |
| Federal Information Security Modernization Act |
Sign up to unlock Jubilant Life Sciences Limited’s security standards, control gaps, and exposure risks.
View Full ReportGet Jubilant Life Sciences Limited's full Non-Financial Risk Report
By signing up, you agree to our Terms and Privacy Policy.